Case report: Thoracic schwannoma as a diagnostic pitfall in both F-Choline PET/CT and F-FDG PET/CT.

We report increased F-FDG uptake in the right posterior mediastinal region in a 70-year-old woman following the discovery of a mass in the aftermath of a bronchitis episode. We also report increased F-Choline uptake in the right posterior mediastinal region in a 66-year-old man with newly discovered prostate cancer, which may indicate the presence of mediastinal metastases. Both patients had a thoracic MRI showing an intense gadolinium enhancement in the same region, consistent with thoracic schwannomas, which were subsequently proven histologically.

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon.

Uveal melanoma (UV) is a rare and aggressive melanoma with poor 1-year survival. up to 50% of UV patients develop metastases, mainly to the liver. Here, the authors present a 2-deoxy-2-[F] fluoro-D-glucose positron emission tomography (F-FDG-PET) study of a very rare case of secondarily metastatic UV in an 81-year-old Caucasian with a dramatic response to pembrolizumab associated with serial pseudogression.

Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on F-FDG-PET/CT.

Eosinophilic fasciitis (EF) is a rare connective tissue disorder causing inflammation and fibrosing of fascia. In this study, we present a very rare case of an immune checkpoint inhibitor (ICI)-induced EF revealed by F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) 20 months after the initiation of Pembrolizumab treatment of a relapsed non-small cell lung cancer (NSCLC). This study presents a 52-year-old Caucasian woman clinically presenting asthenia, inflammatory muscle, and joint pain associated with subcutaneous nodules and symmetrical edema of the lower limbs.

Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents.

We explored antibody response after first and second BNT162b2 vaccinations, to predict the need for subsequent injections in nursing home (NH) residents. 369 NH residents were tested for IgG against SARS-CoV-2 Receptor-Binding Domain (RBD-IgG) and nucleoprotein-IgG (SARS-CoV-2 IgG II Quant and SARS-CoV-2 IgG Alinity assays, Abbott Diagnostics). In NH residents with prior SARS-CoV-2 infection, the first dose elicited high RBD-IgG levels (≥ 4160 AU/mL) in 99/129 cases (76.